HealthMore in Health→
BioNTech, Pfizer Highlight Bispecific Cancer Data as FDA Upheaval Draws Scrutiny
At ASCO, BioNTech and Pfizer promoted new bispecific cancer data while senior FDA oncology official Rick Pazdur argued agency disruption could become a chance to rebuild.
Key Takeaways
- ASCO coverage highlighted BioNTech and Pfizer bispecifics data.
- Rick Pazdur said upheaval at the FDA could create a chance to restructure the agency.
DE
DT Editorial Team··via statnews.com